Home / Publication / Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

論文

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

Author(s): Diana Clarke, Mark Mirochnick, Edward Acosta, Edmund Capparelli, Anne Chain, Hedy Teppler, Betsy Smith, Jos Lommerse

Year: 2019年12月1日

The Reference-scaled Average Bioequivalence (RSABE) Approach

ブログ

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

ブログ

How Model-informed drug development rescue projects from a risky situation

事例紹介

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

論文

Powered by Translations.com GlobalLink Web Software

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

The Reference-scaled Average Bioequivalence (RSABE) Approach

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

How Model-informed drug development rescue projects from a risky situation

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

メルマガ登録

クイックアクセス

ソリューション

お問合せ

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

The Reference-scaled Average Bioequivalence (RSABE) Approach

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

How Model-informed drug development rescue projects from a risky situation​

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

メルマガ登録

クイックアクセス

ソリューション

お問合せ

How Model-informed drug development rescue projects from a risky situation